Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
22 hedge funds and large institutions have $2.44M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 7 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
11% less capital invested
Capital invested by funds: $2.74M → $2.44M (-$302K)
27% less funds holding
Funds holding: 30 → 22 (-8)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$96.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.44K |
| 3 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$4.73K |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$2.25K |
| 5 |
HF
HRT Financial
New York
|
+$1.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$388K |
| 2 |
TI
Telemetry Investments
New York
|
-$151K |
| 3 |
Two Sigma Advisers
New York
|
-$97K |
| 4 |
VF
Virtu Financial
New York
|
-$51K |
| 5 |
Two Sigma Investments
New York
|
-$24K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EWM
26
Elmwood Wealth Management
Berkeley,
California
| – | -$1K | -73 | Closed |
|
27
Morgan Stanley
New York
| – | -$11 | -1 | -33% |
|
28
Bank of America
Charlotte,
North Carolina
| – | +$54 | +5 | +250% |
|
FRTX Hedge Fund Activity: Q1 2022 in Review
22 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q1 2022, worth a combined $2.44M — down 11% from $2.74M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of FRTX and 0 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $96.5K. The largest seller was Renaissance Technologies, cutting an estimated $388K.
- 22 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q1 2022, down from 30 in Q4 2021.
- Funds reported $2.44M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q1 2022, down 11% quarter-over-quarter.
- 0 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q1 2022 and 7 closed out, a net change of -7 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q1 2022 was Vanguard Group, an estimated $96.5K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q1 2022 was Renaissance Technologies, an estimated $388K sold.
Based on aggregated 13F filings for Q1 2022.